TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Researchers analyzing genetic data from nearly 450,000 people identified 42 DNA regions associated with Alzheimer’s risk among people carrying APOE4, including 29 regions not previously reported in this analysis. The findings point to oligodendrocytes and genes such as TNS3 and CISD1 as possible research targets, but need validation and do not establish a treatment or guarantee protection.
Researchers analyzing genetic data from nearly 450,000 people identified 42 DNA regions associated with Alzheimer’s risk among people carrying one or two copies of APOE4, the strongest common genetic risk factor for the disease. The study, published in Alzheimer’s & Dementia, highlights genes active in oligodendrocytes as possible clues to why some APOE4 carriers do not develop Alzheimer’s, but it does not show that these genes can prevent the disease or provide a treatment.
Michael Belloy, an assistant professor at Washington University in St. Louis, and colleagues examined genetic data from people with APOE4, including carriers who had not developed Alzheimer’s. The researchers reported 42 DNA regions linked to APOE4-related risk: 13 had been identified previously, while 29 were new in their analysis. The findings are associations, not proof that the regions directly cause protection.
The team also examined gene activity in post-mortem brain tissue from 424 donors. Many of the genes flagged in the analysis were active in oligodendrocytes, cells that form insulating sheaths around neurons and support the efficient transmission of electrical signals. Belloy pointed to TNS3, which is involved in oligodendrocyte maturation and survival, and CISD1, which is involved in their metabolism, as possible risk modifiers.
The report describes these genes as potential avenues for research, not established drug targets. No FDA-approved medications are identified as targeting TNS3 or CISD1 for Alzheimer’s. The researchers also found that higher MAPT gene activity might be associated with protection, a result Alzheimer’s Drug Discovery Foundation chief scientific officer Laura Nisenbaum said could be relevant to research on tau-lowering approaches. The study does not establish that this finding predicts the effect of a particular therapy.
Oligodendrocytes Emerge as Research Targets
The findings may broaden research beyond APOE4 itself by directing attention to other genetic factors that could modify risk. If further experiments confirm that oligodendrocyte-related pathways contribute to protection, those pathways could offer researchers additional targets to investigate for treatments. The study does not show that changing the activity of these genes would prevent Alzheimer’s in people.
That distinction matters for people with APOE4: the variant raises risk but does not determine an individual outcome. The source report says that about 60 percent of people with two APOE4 copies develop Alzheimer’s over their lifetime, meaning the gene is not a guarantee of disease. The new analysis seeks clues to variation in risk, rather than offering a personal prediction or clinical recommendation.
genetic testing kits for Alzheimer's risk
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Studied APOE4 Carriers
APOE4 is widely recognized as a major common genetic risk factor for Alzheimer’s, but it is not the only influence on whether someone develops the disease. This study focused on genetic variation that might alter risk among people who carry APOE4, including individuals who remained free of a diagnosed Alzheimer’s disease despite that elevated inherited risk.
Researchers paired population-level genetic analysis with gene-activity data from donated brain tissue. These approaches can help identify candidate pathways, but each has limits: genetic associations require replication, and tissue collected after death may not show what was happening earlier in the disease process. The study’s results therefore add leads for follow-up research rather than a settled explanation of protection.
“Ultimately, we found a set of genes that look promising to counter Alzheimer’s disease risk due to APOE4.”
— Michael Belloy, assistant professor at Washington University in St. Louis, speaking to Being Patient
Key Findings Still Need Replication
The report identifies several limits that leave the results provisional. Most participants were of European ancestry, so it is unclear whether the findings apply to other populations. Although participants had a clinical diagnosis, only 40 percent had biomarker confirmation; some diagnoses may therefore have been incorrect.
The post-mortem gene-activity analysis used tissue from people who died in later stages of disease, which may not reflect earlier biological changes. Researchers also have not shown that TNS3, CISD1 or MAPT activity directly protects APOE4 carriers, how large any effect might be, or whether altering these genes would be safe and effective. No treatment benefit or individual-level risk estimate was established by the study.
Validation Before Treatment Applications
Belloy said further experimental and validation studies are needed to test whether the identified signals hold up and to clarify how they might work. Follow-up research will also need to examine whether the results extend to people from ancestry groups underrepresented in this analysis and whether the candidate pathways matter at earlier disease stages.
Until those steps are taken, the study should be understood as a source of possible research targets, not a change in clinical care. The report does not announce a trial of a treatment based on TNS3 or CISD1, and the timing of any such development is not clear. Researchers will need evidence from subsequent studies before these findings can guide drug development or patient decisions.
Key Questions
What did the study find?
Researchers reported 42 DNA regions associated with Alzheimer’s risk among APOE4 carriers, including 29 not previously identified in this analysis. The results point to genes active in oligodendrocytes as possible leads, but do not prove that they protect people from disease.
Does carrying APOE4 mean someone will develop Alzheimer’s?
No. APOE4 raises Alzheimer’s risk, but it does not determine an individual outcome. The source report says about 60 percent of people with two copies develop Alzheimer’s over their lifetime; the study does not provide a personal risk estimate.
Which genes were highlighted?
The report highlights TNS3 and CISD1 as possible risk modifiers linked to oligodendrocyte functions. It also discusses a possible protective association involving MAPT gene activity. These are research findings, not confirmed protective effects.
Is there a treatment based on these findings?
No treatment based on these findings was reported. The source says there are no FDA-approved medications targeting TNS3 or CISD1 that can be repurposed for Alzheimer’s, and further research is needed.
How reliable and broadly applicable are the results?
The findings need validation. Most participants were of European ancestry, and only 40 percent of those with a clinical diagnosis had biomarker confirmation. Those limitations leave questions about generalizability and diagnostic accuracy.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
